Cerebral Palsy and the Potential of Cord Blood Stem Cells Cord Blood Registry® is partnering with two preeminent institutions, the University of Texas Health Science Center at Houston and Georgia Regents University, to establish FDA-regulated clinical trials investigating whether an intravenous infusion of a child’s own cord blood cells, banked at the time of their birth, will lessen the symptoms of cerebral palsy. [PR Newswire Association LLC] Press Release Bioheart Announces Joint Venture with Magnum Cell Therapies Bioheart, Inc. announced that it has entered into a joint venture with Magnum Cell Therapies. Magnum Cell Therapies’ mission is to provide the latest regenerative medicine therapies to patients suffering from degenerative diseases. [Bioheart, Inc.] Press Release Austrianova Contracted by Nuvilex Inc. for cGMP-Compliant Cell-in-a-Box® Encapsulation of Cells Austrianova announced that it has been contracted by Nuvilex, Inc. to produce living encapsulated cells to cGMP (Good Manufacturing Practices) standard. The two companies signed a Manufacturing Framework Agreement that covers all aspects of the production of the encapsulated live cells. [Austrianova] Press Release Budget Unveils £55 Million Large-Scale Cell Therapy Manufacturing Center for the UK The Cell Therapy Catapult, which is focused on the development of the UK cell therapy industry to increase the nation’s health and wealth, is to manage the new UK Cell Therapy Manufacturing Center announced in the budget. The first such UK facility, it is a recognition of the quality and potential of the UK cell therapy community, and will have £55 million of funding from 2014/15. [Cell Therapy Catapult] Press Release $4.25 Million Grant Awarded to Rutgers Cancer Institute of New Jersey and University of Wisconsin Carbone Cancer Center to Develop Innovative Clinical Trials Dr. DiPaola, who was just awarded a $4.25 million grant (UM1CA186716) by the National Cancer Institute of the National Institutes of Health to support a precision experimental therapeutics endeavor, will collaborate with investigators from the University of Wisconsin Carbone Cancer Center on the research that will have a nationwide reach. [Rutgers Cancer Institute of New Jersey] Press Release UC Merced Earns Grant from California’s Stem Cell Push Univeristy of California (UC), Merced Professor Kara McCloskey was awarded a $500,000 grant to continue tackling significant, unresolved issues in human stem cell biology, as part of an effort to enhance stem-cell research in California. [UC Merced] Press Release New DNA-Editing Technology Spawns Bold UC Initiative The University of California (UC), Berkeley, and UC San Francisco are launching the Innovative Genomics Initiative to lead a revolution in genetic engineering based on a new technology already generating novel strategies for gene therapy and the genetic study of disease. The Li Ka Shing Foundation has provided a $10 million gift to support the initiative, establishing the Li Ka Shing Center for Genomic Engineering and an affiliated faculty chair at UC Berkeley. [UC Health] Press Release Pioneering Stem Cell Therapies to Be Trialed in Birmingham University of Birmingham researchers are to lead a worldwide collaboration of scientists looking at the possibility of transplanting stem cells from one person to another to reduce inflammation in the liver. [University of Birmingham] Press Release Cellular Biomedicine Group Launches Development Program for Asthma Stem Cell Therapy Cellular Biomedicine Group Inc. announced the launch of their pre-clinical study on human adipose derived mesenchymal progenitor cell (haMPC) therapy for asthma. The study will evaluate the safety and efficacy of haMPCs to treat severe asthma. [GlobeNewswire, Inc.] Press Release Regenerative Sciences Announces Knee Osteoarthritis Clinical Research Study in Chicago, Illinois Regenerative Sciences, Inc. announced the start of a new clinical research study on the use of autologous stem cells for treating knee osteoarthritis. The study is being conducted in Chicago, Illinois in collaboration with Regenexx Physician Network Provider, Dr. Mitchell Sheinkop. [PR Newswire Association LLC] Press Release ATL1102 for Stem Cell Mobilization Trial Commencement Antisense Therapeutics advised that it has commenced dosing in its Phase I Stem Cell Mobilization Human Proof of Concept trial of ATL1102, the company’s second generation antisense drug targeting the VLA-4 receptor. The trial will assess the safety, tolerability and effect of ATL1102 on the release of hematopoietic stem cells into the blood when dosed alone and in combination with an existing therapy (Granulocyte Colony Stimulating Factor). [PR Newswire Association LLC] Press Release |